Open-source Artificial Pancreas Systems Are Safe and Effective When Supported In-clinic: Outcomes in 248 Consecutive Type 1 Diabetes Clients

Can J Diabetes. 2024 Feb;48(1):59-65.e1. doi: 10.1016/j.jcjd.2023.09.003. Epub 2023 Oct 5.

Abstract

Objective: Our aim in this study was to determine the safety, glycemia, and quality of life (QoL) associated with in-clinic installation and management of supported open-source artificial pancreas systems (SOSAPS) in type 1 diabetes (T1D).

Methods: This investigation is a retrospective cohort study of consecutive SOSAPS users at a Canadian diabetes centre. SOSAPS were offered to all moderately tech-savvy T1D clients on sensor-augmented multiple daily injection or pump, able to pay for hardware, and willing to sign a consent and waiver document. SOSAPS were installed and maintained by clinic staff at no cost to clients. iPhone users were assigned to either Loop (n=108) or iPhone artificial pancreas systems (iAPS; n=114) and Android users to Android-type APS (n=24). Outcomes included severe hypoglycemia and diabetic ketoacidosis (DKA), time in range (TIR) 4.0 to 10.0 mmol/L, time below range (TBR) <4 mmol/L, glucose management indicator (GMI), mean sensor glucose (MSG), change in glycated hemoglobin (A1C), and QoL.

Results: Two hundred forty-eight subjects (131 males, 117 females), with a mean age of 36 years and diabetes duration of 21 years, experienced 3 episodes of severe hypoglycemia and no DKA over a follow-up of 17 months. TIR rose by 16%, from 64% to 80% (p<0.0001); TBR fell by 1.0%, from 3.5% to 2.5% (p=0.001); MSG fell from 9.0 to 8.1 mmol/L (p<0.001); GMI fell from 7.3% to 6.7% (p<0.001); and A1C fell from 7.2% to 6.7% (p<0.0001). QoL scores were healthy before and improved after SOSAPS.

Conclusions: Clients with T1D using SOSAPS and supported with no-cost care to the client (software, technology, and physician/physician assistant) safely achieved improved TIR, GMI, A1C, and QoL.

Keywords: clinical outcomes; closed-loop systems; diabète de type 1; glycemic outcomes; indice glycémique; initiatives dirigées par le patient; patient-driven initiatives; quality of life; qualité de vie; résultats cliniques; systèmes en boucle fermée; type 1 diabetes.

MeSH terms

  • Adult
  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Canada / epidemiology
  • Diabetes Mellitus, Type 1* / drug therapy
  • Diabetic Ketoacidosis* / complications
  • Diabetic Ketoacidosis* / epidemiology
  • Diabetic Ketoacidosis* / prevention & control
  • Female
  • Glucose
  • Glycated Hemoglobin
  • Humans
  • Hypoglycemia* / complications
  • Hypoglycemia* / prevention & control
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Insulin Infusion Systems
  • Male
  • Pancreas, Artificial*
  • Quality of Life
  • Retrospective Studies

Substances

  • Hypoglycemic Agents
  • Glycated Hemoglobin
  • Insulin
  • Glucose
  • Blood Glucose